NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Adicet Bio, Inc. (ACET) Stock Analysis

Adicet Bio, Inc. (ACET) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ACET

$4.49

−$0.03 (−0.66%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ACET with… →

ACET Key Statistics

As of Oct 21, 2026
Trading
Open
$4.52
Previous Close
$4.52
Day's Range
4.44–4.74
52-Week Range
4.39–14.98
Volume
181.83K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.63
Valuation
Market Cap
$42.03M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−10.42
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$116.80M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
9.36M
1-Year Return
−69.56%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
188.52K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ACET closed at $4.49, −69.56% over 1 year.

Adicet Bio, Inc. (ACET) has a market capitalization of $42.03M.

In fiscal 2025, ACET reported revenue of $0.00.

ACET Stock Return by Calendar Year

Adicet Bio, Inc. (ACET) return since Jan 2018: what $10,000 became

1 year
$10,000 $3,044
−69.56%
5 years
$10,000 $328
−96.72%
Since Jan 2018
$10,000 $24
−99.76%

If you had invested $10,000 in Adicet Bio, Inc. (ACET) at the close on January 26, 2018, the earliest close on record here, it would have been worth $24 at the close on October 21, 2026: −99.76% in total, −49.94% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−46.67%
2025−45.30%
2024−49.10%
2023−78.86%
2022−48.89%
2021+24.48%
2020+34.71%
2019−82.71%
2018−48.93%

As of October 21, 2026.

ACET Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$116.80M—
2024$0.00−$117.12M—
2023$0.00−$142.66M—
2022$24.99M−$69.79M−279.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$122.11M−$116.80M—
2024$0.00—−$127.62M−$117.12M—
2023$0.00—−$132.58M−$142.66M—
2022$24.99M—−$72.55M−$69.79M−279.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Adicet Bio, Inc. (ACET) at $42.03M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 102 employees.

The 52-week range on file runs from $4.39 to $14.98. The most recent close on file for ACET is $4.49, dated October 21, 2026. That is −$0.03 (−0.66%) against the previous close. The latest close sits 2.28% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $116.80M. Earnings per share on a trailing basis come to −10.42.

Across the 4 fiscal years on file, revenue moves from $24.99M in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Over the trailing twelve months the total return is −69.56%. Measured over 5 years, that is −49.51% a year compounded. Beta against the wider market is reported at 1.63. Annualized volatility over the trailing 8 years is 93.14%.

Growth & Income

No dividend is on file for ACET.

The strongest complete calendar year on file is 2020 at +34.71%; the weakest is 2019 at −82.71%. Of the 8 complete calendar years on file, 2 finished higher. 2026 is still running; the total return is −46.67% year to date.

Peer Comparison

Adicet Bio, Inc. (ACET) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Adicet Bio, Inc. ACET $42.03M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Adicet Bio, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Adicet Bio, Inc.

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.

Visit website →